2.50
Hdl Handle:
http://hdl.handle.net/10541/69600
Title:
The role of UFT in metastatic colorectal cancer.
Authors:
Bennouna, Jaafar; Saunders, Mark P; Douillard, Jean-Yves
Abstract:
5-Fluorouracil (5-FU) has been the most widely used chemotherapeutic agent for metastatic colorectal cancer (mCRC) and 5-FU combination therapy improves efficacy compared with monotherapy. The oral fluoropyrimidine UFT (tegafur-uracil) with leucovorin (LV) improves tolerability and has replaced 5-FU in many regimens. The efficacy and tolerability of UFT with LV in the first-line treatment of mCRC has been demonstrated in a number of phase II studies. In two phase III studies, UFT with LV has been shown to have comparable efficacy and improved tolerability versus intravenous bolus 5-FU, with very few cases of hand-foot syndrome (HFS). Indirect comparisons of UFT and capecitabine suggest that they are comparable in terms of survival. In first-line treatment, UFT in combination with oxaliplatin (TEGAFOX) or irinotecan (TEGAFIRI) is effective and well tolerated, with similar efficacy and tolerability to the corresponding 5-FU- and capecitabine-based combinations, but with a lower incidence of HFS. Alternating cycles of TEGAFOX and TEGAFIRI are effective and well tolerated, and the combination of TEGAFIRI and the targeted monoclonal antibody cetuximab has shown promising activity, similar to that of FOLFIRI plus cetuximab. UFT can be considered a rational replacement for intravenous 5-FU in the first- and second-line treatment of patients with mCRC.
Affiliation:
Centre R Gauducheau, St Herblain, France. j-bennouna@nantes.fnclcc.fr
Citation:
The role of UFT in metastatic colorectal cancer. 2009, 76 (5):301-10 Oncology
Journal:
Oncology
Issue Date:
2009
URI:
http://hdl.handle.net/10541/69600
DOI:
10.1159/000209334
PubMed ID:
19299903
Type:
Article
Language:
en
ISSN:
1423-0232
Appears in Collections:
All Christie Publications ; Clinical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorBennouna, Jaafar-
dc.contributor.authorSaunders, Mark P-
dc.contributor.authorDouillard, Jean-Yves-
dc.date.accessioned2009-06-02T14:23:13Z-
dc.date.available2009-06-02T14:23:13Z-
dc.date.issued2009-
dc.identifier.citationThe role of UFT in metastatic colorectal cancer. 2009, 76 (5):301-10 Oncologyen
dc.identifier.issn1423-0232-
dc.identifier.pmid19299903-
dc.identifier.doi10.1159/000209334-
dc.identifier.urihttp://hdl.handle.net/10541/69600-
dc.description.abstract5-Fluorouracil (5-FU) has been the most widely used chemotherapeutic agent for metastatic colorectal cancer (mCRC) and 5-FU combination therapy improves efficacy compared with monotherapy. The oral fluoropyrimidine UFT (tegafur-uracil) with leucovorin (LV) improves tolerability and has replaced 5-FU in many regimens. The efficacy and tolerability of UFT with LV in the first-line treatment of mCRC has been demonstrated in a number of phase II studies. In two phase III studies, UFT with LV has been shown to have comparable efficacy and improved tolerability versus intravenous bolus 5-FU, with very few cases of hand-foot syndrome (HFS). Indirect comparisons of UFT and capecitabine suggest that they are comparable in terms of survival. In first-line treatment, UFT in combination with oxaliplatin (TEGAFOX) or irinotecan (TEGAFIRI) is effective and well tolerated, with similar efficacy and tolerability to the corresponding 5-FU- and capecitabine-based combinations, but with a lower incidence of HFS. Alternating cycles of TEGAFOX and TEGAFIRI are effective and well tolerated, and the combination of TEGAFIRI and the targeted monoclonal antibody cetuximab has shown promising activity, similar to that of FOLFIRI plus cetuximab. UFT can be considered a rational replacement for intravenous 5-FU in the first- and second-line treatment of patients with mCRC.en
dc.language.isoenen
dc.subjectCoplorectal Canceren
dc.subject5-FU Combination Therapyen
dc.subjectIrinotecanen
dc.subjectOxaliplatinen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshHumans-
dc.subject.meshTegafur-
dc.subject.meshUracil-
dc.titleThe role of UFT in metastatic colorectal cancer.en
dc.typeArticleen
dc.contributor.departmentCentre R Gauducheau, St Herblain, France. j-bennouna@nantes.fnclcc.fren
dc.identifier.journalOncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.